Woodstock Corp Has $636,000 Stake in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)

Woodstock Corp increased its stake in shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) by 38.3% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 30,778 shares of the company’s stock after purchasing an additional 8,525 shares during the quarter. Woodstock Corp owned approximately 0.06% of EyePoint Pharmaceuticals worth $636,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Deutsche Bank AG increased its position in EyePoint Pharmaceuticals by 4.0% in the 3rd quarter. Deutsche Bank AG now owns 21,764 shares of the company’s stock worth $174,000 after purchasing an additional 830 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its holdings in EyePoint Pharmaceuticals by 6.0% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 15,584 shares of the company’s stock worth $360,000 after buying an additional 882 shares during the last quarter. FNY Investment Advisers LLC bought a new position in EyePoint Pharmaceuticals during the fourth quarter valued at approximately $27,000. Tower Research Capital LLC TRC raised its position in EyePoint Pharmaceuticals by 36.0% during the fourth quarter. Tower Research Capital LLC TRC now owns 4,724 shares of the company’s stock valued at $109,000 after acquiring an additional 1,250 shares in the last quarter. Finally, Toth Financial Advisory Corp lifted its stake in EyePoint Pharmaceuticals by 42.9% in the fourth quarter. Toth Financial Advisory Corp now owns 5,000 shares of the company’s stock valued at $116,000 after acquiring an additional 1,500 shares during the last quarter. 99.41% of the stock is owned by hedge funds and other institutional investors.

EyePoint Pharmaceuticals Stock Down 2.8 %

Shares of NASDAQ EYPT traded down $0.24 during mid-day trading on Thursday, hitting $8.45. The company had a trading volume of 163,009 shares, compared to its average volume of 1,082,411. EyePoint Pharmaceuticals, Inc. has a 12 month low of $5.67 and a 12 month high of $30.99. The business’s 50-day simple moving average is $13.50 and its 200-day simple moving average is $20.00.

EyePoint Pharmaceuticals (NASDAQ:EYPT) last announced its quarterly earnings data on Wednesday, May 8th. The company reported ($0.55) EPS for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.21). EyePoint Pharmaceuticals had a negative return on equity of 49.94% and a negative net margin of 157.77%. The firm had revenue of $11.68 million during the quarter, compared to the consensus estimate of $12.50 million. On average, research analysts forecast that EyePoint Pharmaceuticals, Inc. will post -2.21 EPS for the current year.

Insider Activity at EyePoint Pharmaceuticals

In other EyePoint Pharmaceuticals news, major shareholder Cormorant Asset Management, Lp purchased 850,000 shares of the stock in a transaction on Monday, May 6th. The shares were purchased at an average price of $11.86 per share, with a total value of $10,081,000.00. Following the acquisition, the insider now directly owns 8,325,000 shares of the company’s stock, valued at approximately $98,734,500. The transaction was disclosed in a document filed with the SEC, which is available at this link. In related news, major shareholder Cormorant Asset Management, Lp acquired 850,000 shares of the firm’s stock in a transaction on Monday, May 6th. The shares were bought at an average cost of $11.86 per share, with a total value of $10,081,000.00. Following the completion of the acquisition, the insider now owns 8,325,000 shares of the company’s stock, valued at $98,734,500. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director David R. Guyer sold 11,625 shares of the company’s stock in a transaction that occurred on Tuesday, May 14th. The shares were sold at an average price of $12.65, for a total value of $147,056.25. Following the completion of the sale, the director now owns 5,550 shares in the company, valued at $70,207.50. The disclosure for this sale can be found here. 4.74% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of analysts have weighed in on the company. HC Wainwright reduced their price target on EyePoint Pharmaceuticals from $33.00 to $30.00 and set a “buy” rating for the company in a research report on Monday, May 13th. Chardan Capital dropped their target price on shares of EyePoint Pharmaceuticals from $39.00 to $28.00 and set a “buy” rating on the stock in a report on Tuesday, May 7th. Robert W. Baird decreased their price target on shares of EyePoint Pharmaceuticals from $46.00 to $38.00 and set an “outperform” rating for the company in a report on Wednesday, May 8th. Mizuho dropped their price objective on EyePoint Pharmaceuticals from $39.00 to $30.00 and set a “buy” rating on the stock in a research note on Tuesday, May 7th. Finally, StockNews.com downgraded EyePoint Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, May 9th. One analyst has rated the stock with a sell rating and seven have issued a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $33.29.

About EyePoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.